You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康寧傑瑞製藥(09966.HK)附屬與Pfizer就治療陽性乳腺癌藥物進行臨床試驗研究
阿思達克 03-27 09:37
康寧傑瑞製藥(09966.HK)公布,全資附屬江蘇康寧傑瑞與Pfizer訂立臨床試驗合作與供應協議,就針對人表皮生長因子受體的KN026,聯合Pfizer的產品Ibrance(Palbociclib)的研究進行臨床試驗。

該臨床試驗是一項處於1b期/2期、開放標籤及多中心的研究,以評估KN026聯合Ibrance(Palbociclib)對患有局部晚期不可切除或轉移性HER2陽性乳腺癌患者的有效性、安全性及耐藥性。

根據該協議,Pfizer同意就該臨床試驗向江蘇康寧傑瑞提供Ibrance(Palbociclib),而江蘇康寧傑瑞負責為該臨床試驗提供資金支持並開展該臨床試驗。公司相信,是次合作將對KN026的研究開發及商業化產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account